Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.73 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661698 | 0.85 | CDK2 (0.69) | CDK2SCN9ASCN5AKCNH2MAPT | |
| SCHEMBL6302354 | 0.85 | CDK2 (0.69) | CDK2SCN9ASCN5AKCNH2MAPT | |
| SCHEMBL1678613 | 0.85 | CDK2 (1.00) | CDK2SCN9ASCN5AKCNH2MAPT | |
| SCHEMBL1122444 | 0.82 | CDK2 (0.65) | CDK2SCN9ASCN5AKCNH2MAPT | |
| SCHEMBL16739547 | 0.81 | CDK2 (0.63) | CDK2SCN9ASCN5AKCNH2BRAF | |
| SCHEMBL2932811 | 0.80 | CDK2 (0.66) | CDK2MAPTEGFRNPC1RAB9A | |
| SCHEMBL1121971 | 0.79 | CDK2 (0.70) | CDK2EGFRERBB3KDRBRAF | |
| SCHEMBL6656588 | 0.79 | BRAF (0.62) | CDK2MAPTBRAF | |
| SCHEMBL6659290 | 0.79 | CDK2 (1.00) | CDK2EGFRKDR | |
| SCHEMBL6658632 | 0.78 | CDK2 (0.54) | CDK2MAPTNPC1RAB9AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8222262-B2 | Indazolyl derivatives useful as potassium channel modulating agents | NEUROSEARCH A/S (DK) | 2012-07-17 | — | — | US | disclosed |
| US-8222262-B2 | Indazolyl derivatives useful as potassium channel modulating agents | NEUROSEARCH A/S (DK) | 2012-07-17 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | disclosed |
| US-20090325989-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-12-31 | — | — | US | disclosed |
| US-20090325989-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-12-31 | — | — | US | disclosed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008040753-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNQ5, KCNA5 | CDK2 2402/4885SCN9A 132/4885SCN5A 50/4885 |
| US-20090325989-A1 | INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCND2, KCNN3, KCNJ2 | CDK2 1281/4885SCN9A 202/4885SCN5A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.